Abstract | OBJECTIVE: METHODS: RESULTS: Twenty-two patients were treated with this regimen, and 21 were eligible for safety and efficacy analysis. Eleven (52%) of 21 patients showed a documented partial response (PR), and 11 showed stable disease (SD) by the end of treatment. All the patients who achieved PR reported a significant reduction in pain and improvement in the function of the affected lesions. Median progression-free survival was not reached at the time of analysis. The most common adverse event was abnormalities of the liver transaminases (overall 84.2%). The most common grade 3 or higher toxicity was neutropenia (36.8%), but no febrile neutropenic event was observed. The elevated levels of transaminases were normalized by reducing the dose of methotrexate or delaying treatment. CONCLUSIONS:
|
Authors | Kyong-Hwa Park, Yoon Ji Choi, Kwan-Woo Kim, Kyung-Han Ro, Chang Ho Kang, Sang-Heon Song, Jong Hoon Park |
Journal | Japanese journal of clinical oncology
(Jpn J Clin Oncol)
Vol. 46
Issue 9
Pg. 845-9
(Sep 2016)
ISSN: 1465-3621 [Electronic] England |
PMID | 27365524
(Publication Type: Journal Article)
|
Copyright | © The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: [email protected]. |
Chemical References |
- Antineoplastic Agents
- Vinblastine
- Transaminases
- Methotrexate
|
Topics |
- Adolescent
- Adult
- Aged
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Disease-Free Survival
- Female
- Fever
(etiology)
- Fibromatosis, Aggressive
(drug therapy)
- Humans
- Kaplan-Meier Estimate
- Liver
(enzymology)
- Male
- Methotrexate
(adverse effects, therapeutic use)
- Middle Aged
- Neoplasm Recurrence, Local
- Neutropenia
(etiology)
- Retrospective Studies
- Transaminases
(metabolism)
- Treatment Outcome
- Vinblastine
(adverse effects, therapeutic use)
- Young Adult
|